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ommunity and clinic-based studies have docu-
mented a high lifetime prevalence of psychiatric and
medical comorbidity in bipolar disorder.For example,the
National Comorbidity Survey reported that 95% of
respondents with bipolar disorder also met criteria for
three or more additional lifetime psychiatric disorders.
1,2
In keeping with the view that individuals with bipolar dis-
order are susceptible to comorbid general medical dis-
orders,the Canadian Community Health Survey docu-
mented significantly higher rates of cardiometabolic,
respiratory,neurological,and infectious disorders in indi-
viduals with bipolar disorder.
3
The hazardous effects of psychiatric and medical comor-
bidity provide the impetus for timely detection,diagno-
sis, treatment, and management of comorbidity in the
bipolar population.For example,co-occurring disorders
in bipolar disorder are associated with more severe sub-
types (eg,mixed states),an earlier age at onset,an inten-
sification of symptoms,poor symptomatic and functional
recovery,suicidal behavior,diminished response to phar-
macological treatment,decreased quality of life,as well
as an unfavorable course and outcome.
1,4-6 Moreover,
mortality studies indicate that medical comorbidity (eg,
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It is well established that individuals with bipolar disor-
der are differentially affected by substance-related as
well as medical disorders (ie, cardiometabolic disorders,
respiratory disorders, neurological disorders, and infec-
tious diseases). Emerging evidence indicates that some
comorbid conditions (eg, diabetes mellitus) in bipolar
individuals may be subserved by overlapping neurobio-
logical networks. Disturbances in glucocorticoid/insulin
signaling and immunoinflammatory effector systems are
points of pathophysiological commonality between
bipolar disorder and “stress-sensitive” medical disorders.
Subphenotyping bipolar disorder as a function of comor-
bidity and temporality of onset may provide an oppor-
tunity for refining disease pathophysiological models
and developing innovative disease-modifying therapies.  
© 2008, LLS SAS Dialogues Clin Neurosci. 2008;10:203-213.cardiovascular disease) is the most frequent specific
cause of premature mortality in the bipolar population.
7
The overarching aim of this review is to prioritize future
research vistas regarding comorbidity in bipolar disorder.
Towards this aim,we succinctly review extant literature
on medical and substance use comorbidity,and suggest
translational research opportunities.More comprehen-
sive reviews on the topic of comorbidity in bipolar dis-
order are published elsewhere.
5,8
Method
We conducted a PubMed search of all English-language
articles published between January 1994 and November
2007.The key search terms were:substance use disorder,
alcohol, metabolic syndrome, diabetes, medical comor-
bidity,cardiovascular,respiratory,and infectious disorders,
cross-referenced with bipolar disorder.The search was
supplemented with a manual review of relevant article ref-
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Table I. Current and lifetime prevalence rates of medical comorbidity in bipolar disorder.
Adapted from ref 8: McIntyre RS, Soczynska JK, Beyer JL, et al. Medical comorbidity in bipolar disorder: re-prioritizing unmet needs. Curr Opin Psychiatry.
2007;20:406-416. Copyright © Rapid Science Publishers 2007.
Comorbid condition Mean rate of  Percentage range  Mean rate of  Range across  References
comorbidity (%) across studies (%) comorbidity (%) studies (%)
Current Lifetime
Arthritis 14 12-16 19 16-21 3,9-13
Asthma 3 18 6-35 9,14
Benign prostatic hyperplasia/ hypertrophy 3 1-5 8 3,9,10
Cancers 2 1-3 2 1-2 3,9,14,15
Cardiovascular comorbidities 23 11-35 26 4-49 9,10,13
Chronic obstructive pulmonary disease 9 8-11 6 3-9 10,16
Dementia/ Alzheimer’s disease 3 5 9,10,14
Dermatologic comorbidities 7 28 20-45 3,9,10,14,15,17,18-20
Diabetes mellitus 10 4-17 11 2-26 9,10,17
Dyslipidemias including hypercholesterolemia,
hyperlipidemia, hypertriglyceridemia 29 23-41 29 9
Endocrine comorbidities 23 29 3,9,10,14
Gastrointestinal comorbidities 12 7-18 35 11-56 9,14
Genitourinary comorbidities 9 39 21-56 10,11,13,14,21-24
Headache/ migraine 4 29 15-44 9
Hepatic comorbidities 17 21 9,10,15
Hepatitis C 7 2-14 16 25
HIV 21 3,10,13,17,26,40
Hypertension 26 2-39 24 10-33 10,14
Injuries 12 13 10
Lower back pain 15 17
Metabolic syndrome 30 9,14
Musculoskeletal comorbidities 23 63 50-75 27-29
Neurological comorbidities 35 17-53 14,17,30-35
Obesity 31 19-49 18 3-33 30,32,34,36
Overweight 54 36-68 9,10
Pancreatitis 2 1-4 2 10
Parkinson’s disease 0.05 3,9,14,15,37
Pulmonary comorbidities 7 1-13 25 8-43 9,10
Renal comorbidities 2 1-2 7 9,10,26
Stroke 2 1-2 3 3,9,10,12,14,26,38
Thyroid disorders 12 7-19 13 7-16 39+-erence lists.Articles selected for review were based on the
author’s consensus on the adequacy of sample size,the use
of standardized diagnostic instruments,validated assess-
ment measures,and overall manuscript quality.
Medical and substance use comorbidity in
bipolar disorder
Table I provides an overview of the comorbidity of other
medical conditions and substance use with bipolar dis-
order.
Cardiometabolic disorders
Circulatory disorders
The age-adjusted rate of circulatory disorders in the
bipolar population is significantly higher,with a younger
mean age at onset, when compared with individuals in
the general population.High rates of hypertension com-
prise a risk factor for sudden cardiovascular death and
cerebrovascular accidents.
40 Cardiovascular disease risk
reduction should be a primary behavioral strategy in
bipolar individuals based on results from mortality 
studies.
26,41,42
Obesity
Results from several cross-sectional and longitudinal
studies indicate that overweight,obesity,abdominal obe-
sity,and mood disorders co-occur.
30,33,36,43-46The high rate
of co-occurrence of obesity and mood disorders provides
the basis for hypothesizing that both phenotypes share
common moderating and mediating variables.
30,32,36,47,48
Risk factors for obesity identified in individuals with
bipolar disorder are gender,income,educational attain-
ment,physical activity level,and treatment with weight-
gain-promoting agents.
32,36 Additional determinants of
body weight are total daily intake of simple carbohy-
drates,total caloric intake,caffeine consumption,comor-
bid binge-eating disorder, and number of previous
depressive episodes.
32,49
Intensified research efforts have reported that obesity is
associated with a multiepisodic course,suicidality,depres-
sion severity, decreased probability of symptomatic
remission,and shorter time to episode recurrence,when
compared with healthy-weight individuals with bipolar
disorder.
50,51
Type 2 diabetes mellitus
Compelling evidence suggests that the prevalence of
type 2 diabetes mellitus is increased several-fold in
bipolar disorder (Table II). Moreover, results from
descriptive studies evaluating metabolic disorders in
US and European academic centers indicate that 
the prevalence of National Cholesterol Education
Program-Adult Treatment Panel III (NCEP ATP III,
US) or International Diabetes Federation (Europe)-
defined metabolic syndrome is also increased in bipo-
lar individuals.
17,52,53
Taken together, individuals with bipolar disorder are
differentially affected by hyperglycemia,abnormal glu-
cose tolerance, and type 2 diabetes mellitus, as well as
several other components of the metabolic syndrome.
Respiratory diseases 
Individuals with bipolar disorder evince higher rates of
pulmonary disorders including pulmonary embolism,
bronchitis, chronic obstructive pulmonary disease, and
asthma.The high rates of pulmonary disorders are due
to the clustering of established risk factors in the bipo-
lar population (eg, medication and illness-associated
immobilization [eg, seclusion and restraints], muscu-
loskeletal trauma,hypercoagulability,diabetes mellitus,
illicit drug use, obesity, habitual inactivity, and smok-
ing).
3,7,37,54
Neurological disorders
Rates of migraine headache, seizure disorder, multiple
sclerosis, traumatic brain injury, and cerebrovascular
accidents are increased in the bipolar population.
8 The
most common neurological comorbidity in bipolar dis-
order,notably bipolar II disorder,is migraine headache.
For example, results from the Canadian Community
Health Survey indicated that individuals with bipolar
disorder exhibited a threefold (24.8% vs 10.3%) greater
adjusted rate for migraine headache when compared
with the general population.
21 Other epidemiological
studies have similarly reported a greater hazard for
migraine amongst bipolar populations.
55 The probabil-
ity that an individual with bipolar disorder is affected
by a comorbid neurological disorder is partially influ-
enced by the topographical localization of the neuro-
logical pathology.
21,39,56-59
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Table II. Prevalence of diabetes mellitus (DM) in bipolar disorder (BD).
Adapted from ref 8: McIntyre RS, Soczynska JK, Beyer JL, et al. Medical comorbidity in bipolar disorder: re-prioritizing unmet needs. Curr Opin Psychiatry.
2007;20:406-416. Copyright © Rapid Science Publishers 2007. References cited in original article.
Comments
- 0/34 (0%) IV dextrose tolerance 
tests abnormal
- 6/30 (20%) oral dextrose tolerance 
“retarded decline” in blood sugar
- “(no) evidence of an intrinsic disorder 
of carbohydrate metabolism”
- 16/42 (38%) manic-depressive patients 
exhibit “hyperglycemic response”
- 6/42 (14%) schizophrenics patients 
exhibit “hyperglycemic response”
- 9/17 (53%) manic-depressive patients 
exhibited a “hyperglycemic response”
- 20/203 (10%) were diagnosed with DM
- 4/79 males, 16/124 females (13%)
- patients older than 45 years old, 
prevalence of DM 18% women, 6% men
- patients older than 65 years, 
prevalence of DM 23% and 16%, 
for women and men respectively
- 16/129 (12.4%) manic-depressive 
on diabetic diet
- 38/1134 (3.3%) schizophrenic
- 121/4379 (2.8%) overall
- 81/114 (71%) had a lifetime history of 
one criteria-defined psychiatric illness
- 3/114 (3%) diagnosed with 
manic depression
- 37/114 (33%) diagnosed with 
depression
- significant difference in glycated 
hemoglobin was observed in patients 
with a recent psychiatric illness (10.8%) 
to those never psychiatrically ill (9.6%)
- psychiatric patients reported more 
symptoms of poor metabolic control 
and more distress associated with the 
symptoms than did patients never 
psychiatrically ill
- 36/357 (10%) diagnosed with DM
- Total number of psychiatric 
hospitalizations significantly greater in 
diabetic group than in the age-matched 
comparison (non-diabetic BD patients)
Patients
N=30 Manic-depressive (pre-DSM) 
N=6 manic, N=18 depressed, 
N=6 agitated depression
Patients mostly treated
Age: 18-64
N=42 Manic-depressives 
(“mostly unmedicated”) Age: 18 - 71
N=42 Schizophrenic patients
All patients >40 years old
N=17 Manic- Depressives (lithium naïve)
Age: 48 – 86
N=203 Manic-depressives (DSM-II) 
DM defined as patients who were given  
a clinical diagnosis based on fasting blood 
sugar or substantiated medical history
Patients mostly treated 
N=4508 total number of individuals 
discharged between 1973-78 with 
diabetic diet recorded in dietary record
Patients mostly treated 
Age: 18 –79
N=114 diabetic patients random 
recruitment evaluated with National 
Institute of Mental Health Diagnostic 
Interview Schedule (DSM-III)
Mean Age – 40 +/- 15.1
N=345 BD patients (DSM-III-R)
DM diagnosis based on clinical analysis 
of blood glucose.
Patients mostly treated 
Age: 20 –74
Author and year Study design
Gildea et al, 1943  Oral and intravenous 
dextrose tolerance test
Van der Velde et al, 1968a Oral glucose 
tolerance test
Van der Velde et al, 1968b  Oral glucose 
tolerance test
Lilliker, 1980a  Retrospective chart 
review
Lilliker,1980b Retrospective chart review
Lustman et al, 1986  Cross-sectional evaluation
Cassidy et al, 1999  Retrospective chart reviewMedical and substance use comorbidity in bipolar disorder - McIntyre et al Dialogues in Clinical Neuroscience - Vol 10 . No.2 . 2008
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Table II. Continued
Comments
- Study designed to assess glucose-
induced changes in memory performance
- Plasma glucose higher in schizophrenia 
than BD and normal control
- Higher insulin levels in both schizophre-
nia and BD than normal controls
- Rates of type II DM among the five 
groups were: schizoaffective 10/20 (50%),
BD-I 14/53 (26%), major depression 
12/65 (18%), dementia 6/64 (95%). 
Schizophrenia 9/71 (13%)
- Diabetic patients had higher body 
mass index (BMI), but not a significantly 
higher use of psychotropic medication
- Compared with national norms, DM 
rates were significantly elevated in BD-I, 
and schizoaffective patients 
- 26/222 (12%) had DM
- BD with comorbid DM were older 
(53 +/- 9 vs 43 +/- 12), chronically ill, 
rapid cycling, lower Global Assessment 
of Function score
- BD with comorbid DM higher long-term
disability, higher BMI (34 +/- 6 vs 29 
+/- 6), higher rate of hypertension
- 83/171 (49%) had abdominal obesity
- 81/171 (48%) were hypertriglyceridemic 
or were on a cholesterol-lowering 
medication
- 38/171 (23%) had low HDL-cholesterol
- 67/171 (39%) had high blood pressure
- 13/171 (8%) were high in fasting 
glucose or were on antidiabetic 
medication
- 51/171 (30%) met criteria for the 
metabolic syndrome (presence of least 
3 of the above)
- 54% of the diabetic patients with 
schizophrenia, 64% with a mood 
disorder, and 71% without a mental 
illness met the NCEP definition of 
metabolic syndrome
- Uncomplicated diabetes BD N=146 
(4.1%); C=17205 (2.4%)
- Complicated diabetes BD N=63 (1.8%); 
C=4401 (0.6%)
Patients
Schizophrenia N=10, BD N=10,
Healthy controls N=11
(DSM-III-R)
Patients mostly treated 
Age: 35.1+/- 10.2
N=243 BD (DSM-IV)
DM defined based on clinical diagnosis in 
chart, OR the prescription of insulin or 
oral hypoglycemics (upon discharge)
Comparison with four other 
diagnostic groups
Patients mostly treated
Age: 50-74
BD-I N=151
BD-II N=65
BD Not otherwise specified N=6
(DSM-IV)
DM ascertained based on previous 
diagnosis and evidence of treatment
Patients mostly treated
Age:15 –72 
BP-I N=121
BP-II N=45
BP NOS=5
(DSM-IV)
Metabolic syndrome defined based on 
National Cholesterol Education 
Program (NCEP)
Adult Treatment Panel III
Age: >18
Schizophrenia and DM N=50
Major mood disorder and DM N=45
Without mental illness and DM N=48
Age: 18 –65
N=3557 bipolar I disorder; control (C) 
population=726,262
Author and year Study design
Newcomer et al, 1999  Oral glucose tolerance test: 
15-, 45-, 75- min post 
ingestion blood sampling
Regenold et al, 2002  Retrospective chart review
Ruzickova et al, 2003  Retrospective analysis 
of the Maritime 
Bipolar Registry
Kessing et al, 2004  Retrospective Danish 
national registry
Kreyenbuhl et al, 2006 Retrospective chart review
Carney and Jones, 2006 Retrospective administrative 
claims databaseThyroid disorders and infectious diseases
Disorders of the hypothalamic pituitary thyroid
(HPT) axis are commonly reported in individuals
with bipolar disorder.
60 Rates of hyper- and hypothy-
roidism, as well as subclinical alterations in the HPT
axis are increased, and associated with rapid cycling
and diminished treatment responsiveness.
61 Bipolar
individuals are also at risk for infectious diseases
(eg, hepatitis C, human immunodeficiency virus
[HIV]) largely due to risk factor clustering (eg,
lower socioeconomic status and substance use dis-
orders).
15,39
Substance use disorders 
The Epidemiological Catchment Area (ECA) Study
and National Comorbidity Survey (NCS) reported a
lifetime prevalence of alcohol dependence of 13.5%
and 14.1%,respectively in the US general population.
The lifetime prevalence of non-alcohol drug depen-
dence was also reported at 6.1% and 7.5%, respec-
tively. Results from the ECA and NCS studies cohere
with results from the recent National Epidemiological
Survey on Alcohol and Related Conditions
(NESARC) that documented a greater hazard for
alcohol and drug abuse or dependence amongst bipo-
lar individuals.
62,63
The harmful effects posed by substance use disorder in
bipolar populations have been documented in many
studies.
5,64Taken together,alcohol and substance use dis-
order are associated with high rates of treatment nonad-
herence,low rates of recovery,greater risk of aggression
and violence,increased rate of attempted and completed
suicide, as well as a less favorable response to conven-
tional treatment.
65
Comorbidity research in bipolar disorder:
future vistas
Medical comorbidity and substance use disorders
are prevalent and hazardous conditions in the bipo-
lar population. Future research vistas should
attempt to parse out neurobiological mediators that
subserve medical comorbidity as well as temporal-
ity of onset. Such efforts may inform mechanistic
models as well as individualized treatment plan-
ning.
Biological mediators of “stress-sensitive”
medical disorders 
Glucose-insulin homeostasis
The differential occurrence of “stress-sensitive”medical
disorders in the bipolar population suggests that interact-
ing effectors mediating stress are a point of pathophysio-
logical commonality.In keeping with this view,a testable
hypothesis is that some features of bipolar disorder are
affected by disturbances in metabolic networks.For exam-
ple, it is documented that neurocognitive deficits are a
prevalent and enduring trait abnormality associated with
impairment in psychosocial functioning and reduced qual-
ity of life in bipolar disorder.
66-75 Moreover,reports of dis-
parate neurocognitive deficits (eg,nonverbal and verbal
intelligence,information processing,visuospatial ability,
attention,executive function,learning,and memory) have
been documented in diabetic populations for several
decades (ie,diabetic encephalopathy).
76Taken together,
these separate lines of evidence indicate glucose-insulin
homeostatic network disturbances are critical mediators
of abnormal central nervous system structure and function
in mood disorders.
75,77-84
Inflammatory networks
A growing body of literature indicates that cytokine-
mediated inflammatory processes are implicated in the
pathophysiology of numerous medical and neurological
conditions.
85 Cytokines are nonantibody proteins that act
as mediators of physiological and pathophysiological cel-
lular processes.For example,elevated proinflammatory
cytokines (eg,interleukin [IL]-1,tumor necrosis factor
[TNF]·) have been associated with an accumulation of
amyloid-β, the pathophysiological hallmark of
Alzheimer’s disease.
86-88
Peripherally and centrally-derived cytokines traverse the
blood-brain barrier at circumventricular organs.
89,90
Furthermore,cytokines play a key role in the activation
of the hypothalamic-pituitary-adrenal (HPA) axis and
peripheral glucocorticoid signaling.Chronic activation of
the HPA axis has been associated with immunosuppres-
sion,as well as alterations in noradrenergic,dopaminer-
gic,and serotonergic pathways.
91
It is well established that proinflammatory cytokines
induce “sickness behavior,”a symptom complex pheno-
typically similar to the somatic depressive symptoms of
Clinical research
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Proinflammatory cytokine activation is also associated
with a reduction in cognitive performance and abnormal
brain activation patterns.
92,93 For example,elderly persons
with high IL-6 plasma concentrations are more likely to
exhibit a decline in cognitive function.
94 Infusion of an
endotoxin to healthy individuals has also been demon-
strated to induce cognitive deficits in both verbal and
visual memory.
95 Preliminary results also document an
elevated proinflammatory cytokine profile (eg, IL-8,
TNF-α) in bipolar disorder during active depressive or
manic states.
92,96,97
Substance use comorbidity: 
subphenotyping temporality of onset and
shared neurobiology?
The effect of temporality of onset of bipolar disorder on
alcohol/substance use disorders may provide a more
refined view of the association between bipolar disorder
and comorbidity syndromes.
98 For example,Strakowski
et al reported that the relative onset of alcohol use dis-
orders in bipolar disorder affects the subsequent courses
of illness in patients with both conditions.
99 Individuals
for whom the alcohol use disorder antedates the onset of
bipolar disorder were significantly more likely to be
older,have higher educational attainment,have a later
age at onset of bipolar disorder,exhibit psychosis,recover
from the index episode,and less likely to evince mixed
states.Conversely,individuals presenting with bipolar ill-
ness first exhibited more rapid cycling,mixed states,more
time with affective episodes,and symptoms of an alcohol
use disorder during follow-up.
A separate analysis evaluating co-occurring cannabis use
in the course of bipolar disorder after a first hospitaliza-
tion for mania reported that the effect of the sequence of
onset of bipolar in cannabis use disorder was less pro-
nounced than observed in co-occuring alcohol and bipo-
lar disorder.The cannabis-first group exhibited a higher
recovery rate,although when adjusted for potential medi-
ating variables the results did not persist.Cannabis use
was associated with more time spent in affective episodes
and rapid cycling.
99
A defining characteristic of addiction is the overpower-
ing motivational strength and decreased ability to con-
trol the desire to obtain a substance despite economic,
social,and/or health-related consequences.
44,100,101 Obesity
is increasingly viewed as a consequence of an addictive
behaviour;that is,foraging and ingestion habits persist
and strengthen despite the threat of catastrophic conse-
quences.
100,102-108 Moreover,it is conjectured that both obe-
sity and substance use disorders are subserved by an
overlapping,and aberrant,reward-motivation neural net-
work (eg, ventral tegmental-nucleus accumbens cir-
cuit).
100,109-113 Further evidence for the role of dopamine as
a salient neurotransmitter in brain reward circuitry is
provided by neuroimaging studies which report an
inverse relationship between body mass index (BMI) and
the striatal density of dopamine D2 receptors.
100,114-117
A testable hypothesis is that the inverse relationship
between alcohol use and BMI may be a phenotypic
expression of a competing brain reward system.A candi-
date neurotransmitter salient to this process may be
dopamine.
100,101,118,119 For example,pharmacological block-
ade of,or experimental damage to,forebrain dopamine
systems (eg,the ventral tegmental-nucleus accumbens cir-
cuit) has been shown to attenuate free feeding and lever-
pressing for food reward while suppressing the rewarding
effects of cocaine,amphetamine,nicotine,and alcohol.
101
In keeping with the view that aberrant neural circuitry
may subserve substance use disorders and over-
weight/obesity in bipolar disorder,McIntyre et al,utiliz-
ing data from the cross-national CCHS epidemiological
study,reported that overweight/obese bipolar individu-
als had a significantly lower rate of substance depen-
dence (13.0% vs 21.4%) as compared with the normal
weight bipolar individuals.
120 Similarly,substance-depen-
dent bipolar individuals displayed a lower rate of over-
weight/obesity as compared with non-substance-depen-
dent bipolar individuals (39% vs 54%). The negative
association between overweight/obesity and substance
dependence amongst the bipolar respondents remained
statistically significant in multivariate analysis control-
ling for several possible confounding variables.
Conclusion
A concatenation of descriptive study results have pro-
vided compelling evidence that the bipolar population is
differentially affected by several medical disorders and
substance-use disorders.Shifting priority towards sub-
phenotyping bipolar disorder as a function of comorbid-
ity offers an opportunity to refine disease models and
possible etiological determinants.
Dissection of the observable characteristics of complex
disorders (ie,excluding dimensions of the syndrome that
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reduce heterogeneity,thereby enhancing the resolution
of linkage analysis.For example,a susceptibility gene for
breast cancer,a prototypical multifactorial medical dis-
ease,was discovered after data for families with early-
onset breast cancer,and a high vulnerability to ovarian
cancer,were analyzed separately from data for families
with late-onset breast cancer.
121
Recent associations between bipolar disorder and other
chronic inflammatory disorders suggest that individuals
with bipolar disorder and comorbid inflammatory-based
medical disorders may constitute a distinct population.
122
Subphenotyping bipolar and substance use disorders on
the basis of sequence of onset,as well as associations with
other addictive disorders (eg, food consumption) are
hitherto understudied.Emerging evidence indicates that
temporality of onset defines separate subpopulations of
bipolar disorder with differential course,outcome,and
treatment response.
Despite the ubiquity of comorbidity in bipolar disorder,
the evidentiary base informing therapeutic decisions in
the comorbid bipolar patient remains woefully inade-
quate.
123-126 Nevertheless, clinicians should endeavor to
ensure that individuals with bipolar disorder receive
treatment as part of a chronic disease management
model which includes self-management, integrative
community-based programs, age-specific assessments
for medical risk factors and laboratory abnormalities
multimodality remission-focused treatments,and a lon-
gitudinal provision of care.
3,9-11 ❏
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